Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Share-based Compensation (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Share-based Compensation for 16 consecutive years, with $9.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 38.34% to $9.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.9 million through Dec 2025, up 29.26% year-over-year, with the annual reading at $37.9 million for FY2025, 29.26% up from the prior year.
  • Share-based Compensation hit $9.8 million in Q4 2025 for Ani Pharmaceuticals, up from $9.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $9.8 million in Q4 2025 to a low of $3000.0 in Q3 2021.
  • Historically, Share-based Compensation has averaged $5.0 million across 5 years, with a median of $5.3 million in 2023.
  • Biggest five-year swings in Share-based Compensation: tumbled 86.96% in 2021 and later skyrocketed 54340.0% in 2023.
  • Year by year, Share-based Compensation stood at $3.0 million in 2021, then grew by 25.91% to $3.7 million in 2022, then soared by 50.41% to $5.6 million in 2023, then increased by 25.62% to $7.1 million in 2024, then surged by 38.34% to $9.8 million in 2025.
  • Business Quant data shows Share-based Compensation for ANIP at $9.8 million in Q4 2025, $9.7 million in Q3 2025, and $9.6 million in Q2 2025.